Stevanato Group S.p.A. (STVN)
USD 22.47
(-5.07%)
USD 22.47
(-5.07%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 242.73 Million EUR | 63.56% |
| 2022 | 148.4 Million EUR | -26.37% |
| 2021 | 201.56 Million EUR | -31.47% |
| 2020 | 294.12 Million EUR | -3.71% |
| 2019 | 305.44 Million EUR | 16.4% |
| 2018 | 262.41 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 240.64 Million EUR | -10.23% |
| 2024 Q1 | 268.16 Million EUR | 10.47% |
| 2023 Q3 | 196.3 Million EUR | 62.4% |
| 2023 Q2 | 120.87 Million EUR | -15.63% |
| 2023 FY | 242.73 Million EUR | 63.56% |
| 2023 Q1 | 143.27 Million EUR | -3.46% |
| 2023 Q4 | 242.73 Million EUR | 23.65% |
| 2022 Q3 | 170.81 Million EUR | -2.64% |
| 2022 Q2 | 175.44 Million EUR | -10.85% |
| 2022 FY | 148.4 Million EUR | -26.37% |
| 2022 Q1 | 196.8 Million EUR | -2.36% |
| 2022 Q4 | 148.4 Million EUR | -13.12% |
| 2021 Q1 | 282.54 Million EUR | -3.94% |
| 2021 FY | 201.56 Million EUR | -31.47% |
| 2021 Q3 | 237.11 Million EUR | -10.37% |
| 2021 Q2 | 264.55 Million EUR | -6.37% |
| 2021 Q4 | 201.56 Million EUR | -14.99% |
| 2020 Q4 | 294.12 Million EUR | 0.0% |
| 2020 FY | 294.12 Million EUR | -3.71% |
| 2020 Q1 | - EUR | 0.0% |
| 2019 FY | 305.44 Million EUR | 16.4% |
| 2018 FY | 262.41 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alcon Inc. | 4.59 Billion USD | 94.714% |
| AptarGroup, Inc. | 726.45 Million USD | 66.586% |
| Baxter International Inc. | 11.06 Billion USD | 97.806% |
| Becton, Dickinson and Company | 14.73 Billion USD | 98.353% |
| Bausch + Lomb Corporation | 4.53 Billion USD | 94.644% |
| Haemonetics Corporation | 797.56 Million USD | 69.565% |
| Envista Holdings Corp | 1.5 Billion USD | 83.904% |
| ResMed Inc. | 697.31 Million USD | 65.19% |
| Teleflex Incorporated | 1.83 Billion USD | 86.8% |
| Warby Parker Inc. | 150.17 Million USD | -61.639% |
| West Pharmaceutical Services, Inc. | 157.3 Million USD | -54.313% |